AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36148886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tumour size
Number of subjects: 56
Study 36148886 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian cycle (morning vs. afternoon)
Number of subjects: 56
Study 36148895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1395
Study 36148919 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 0
Study 36148919 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline variants identified in patients with positive family history (8 of 19 patients, 42.1%)
Number of subjects: 245
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline variants identified in sporadic patients (23 of 226 patients, 10.2%)
Number of subjects: 245
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic variants identified in tested individuals (20 of 119 tested individuals, 16.8%)
Number of subjects: 245
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall variants of interest identified at the germline level (12.2% of patients)
Number of subjects: 245
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall variants of interest identified at the somatic level (7.8% of patients)
Number of subjects: 245
Study 36149413 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexisting germline and somatic variants (0.4% of patients)
Number of subjects: 245
Study 36149729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating apps (Jack'D)
Number of subjects: 254
Study 36149729 — intervention group
Group type: COMPARATOR
Intervention: Social media sites (Instagram)
Number of subjects: 254
Study 36149729 — intervention group
Group type: COMPARATOR
Intervention: Information search sites (Bing)
Number of subjects: 254
Study 36149737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Number of subjects: 40
Study 36149737 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no immediate intervention)
Number of subjects: 40
Study 36149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
Number of subjects: 0
Study 36149743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) for SMC
Number of subjects: 0
Study 36149743 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+AQ and piperaquine-resistance markers
Number of subjects: 0
Study 36149743 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC implementation model
Number of subjects: 0
Study 36149832 — intervention group
Group type: EXPERIMENTAL
Intervention: Darvadstrocel (24-mL intralesional injection, 120×106 cells)
Number of subjects: 22
Study 36150047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 36150047 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 36150047 — intervention group
Group type: COMPARATOR
Intervention: Negative/unknown thrombophilia
Number of subjects: 0
Study 36150050 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib 100mg daily
Number of subjects: 23
Study 36150050 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib maintenance therapy
Number of subjects: 23
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: IAA-first autoantibody predictors
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA-first autoantibody predictors
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from single to multiple autoantibodies
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to diabetes
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to multiple autoantibodies
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression from multiple autoantibodies to diabetes
Number of subjects: 8502
Study 36150053 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly reported SNPs
Number of subjects: 8502
Study 36150143 — intervention group
Group type: EXPERIMENTAL
Intervention: Valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity
Number of subjects: 25
Study 36150208 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain (GWG)
Number of subjects: 184
Study 36150208 — intervention group
Group type: COMPARATOR
Intervention: Recommended gestational weight gain (GWG)
Number of subjects: 184
Study 36150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study 36150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity tertiles
Number of subjects: 0
Study 36150365 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured biomarkers
Number of subjects: 0
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine (CoronaVac) administered in two doses (28-days interval) with a booster at day 210.
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFi)
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: SSZ+TNFi combination
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of vaccine (D69-D240)
Number of subjects: 194
Study 36150668 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi
Number of subjects: 194
Study 36150750 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-image ganglion cell complex (wiGCC) thickness
Number of subjects: 238
Study 36150750 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-image vessel density (wiVD)
Number of subjects: 238
Study 36150926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (IV and/or SC administration)
Number of subjects: 1673
Study 36151216 — intervention group
Group type: EXPERIMENTAL
Intervention: CD7-targeting CAR-T cells (RD13-01)
Number of subjects: 12
Study 36151335 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency source control intervention (< 2 h of diagnosis)
Number of subjects: 2621
Study 36151335 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent source control intervention (2-6 h of diagnosis)
Number of subjects: 2621
Study 36151335 — intervention group
Group type: COMPARATOR
Intervention: Delayed source control intervention (> 6 h of diagnosis)
Number of subjects: 2621
Study 36151335 — intervention group
Group type: COMPARATOR
Intervention: Septic shock
Number of subjects: 2621
Study 36151335 — intervention group
Group type: COMPARATOR
Intervention: Late-onset hospital-acquired peritonitis
Number of subjects: 2621
Study 36151335 — intervention group
Group type: COMPARATOR
Intervention: Failed source control evidenced by persistent inflammation at day 7
Number of subjects: 2621
Study 36151335 — intervention group
Group type: COMPARATOR
Intervention: Appropriate empiric therapy
Number of subjects: 2621
Study 36151773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in combination with VIT (vincristine, irinotecan, and temozolomide) at Dose Level 4 (1666 mg/m2)
Number of subjects: 26
Study 36151773 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in combination with VIT
Number of subjects: 26
Study 36151945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult clinic sites
Number of subjects: 0
Study 36151945 — intervention group
Group type: COMPARATOR
Intervention: Pediatric clinic sites
Number of subjects: 0
Study 36151975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-specific risk factors in permissive environments
Number of subjects: 0
Study 36151975 — intervention group
Group type: COMPARATOR
Intervention: Permissiveness of the cannabis environment
Number of subjects: 0
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with hypertension
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with hyperlipidemia
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with diabetes
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with obesity
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 387
Study 36152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 387
Study 36152144 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day)
Number of subjects: 554
Study 36152216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 719
Study 36152216 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab with or without TCS
Number of subjects: 719
Study 36152218 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab-treated patients with aHUS and malignant hypertension
Number of subjects: 1097
Study 36152218 — intervention group
Group type: COMPARATOR
Intervention: Not-treated patients with malignant hypertension
Number of subjects: 1097
Study 36152218 — intervention group
Group type: COMPARATOR
Intervention: Not-treated patients with aHUS
Number of subjects: 1097
Study 36152227 — intervention group
Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 and Flu A/B Test
Number of subjects: 283
Study 36152767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3P machine learning model (platelet count, bilirubin, international normalised ratio)
Number of subjects: 1232
Study 36152767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5P machine learning model (platelet count, bilirubin, activated partial thromboplastin time, gamma-glutamyltransferase, choline-esterase)
Number of subjects: 1232
Study 36152767 — intervention group
Group type: EXPERIMENTAL
Intervention: 3P machine learning model
Number of subjects: 1232
Study 36152767 — intervention group
Group type: EXPERIMENTAL
Intervention: 5P machine learning model
Number of subjects: 1232
Study 36152767 — intervention group
Group type: COMPARATOR
Intervention: Liver stiffness measurement
Number of subjects: 1232
Study 36152902 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Spinal Nerve Neuromodulation Therapy
Number of subjects: 0
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor agents
Number of subjects: 10206
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 10206
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 10206
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine/thiopurines
Number of subjects: 10206
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Number of subjects: 10206
Study 36152897 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 10206
Study 36153018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for time to pregnancy
Number of subjects: 1931
Study 36153018 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1931
Study 36153561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0
Study 36153609 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey sinus rinse
Number of subjects: 30
Study 36153609 — intervention group
Group type: COMPARATOR
Intervention: Standard sinus rinse (control)
Number of subjects: 30
Study 36154291 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36154854 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood samples
Number of subjects: 36
Study 36154854 — intervention group
Group type: COMPARATOR
Intervention: Venous blood samples
Number of subjects: 36
Study 36155150 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma l-carnitine
Number of subjects: 646
Study 36155150 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma l-carnitine (highest tertile)
Number of subjects: 646
Study 36155150 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 646
Study 36155150 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls free of recurrent cardiovascular events)
Number of subjects: 646
Study 36155347 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid advertisements on Facebook
Number of subjects: 407769
Study 36155347 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid posts on the MAGENTA Facebook page
Number of subjects: 407769
Study 36155347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Facebook outreach (paid and unpaid)
Number of subjects: 407769
Study 36155347 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged ≥65 years
Number of subjects: 407769
Study 36155347 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media outreach
Number of subjects: 407769
Study 36155396 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Artificial Intelligence System
Number of subjects: 60
Study 36155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation
Number of subjects: 0
Study 36155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab)
Number of subjects: 0
Study 36155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy based regimens
Number of subjects: 0
Study 36155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with anti-PD-1/PD-L1 or anti-CTLA4 antibodies
Number of subjects: 0
Study 36155490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of new strategies
Number of subjects: 0
Study 36155747 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Number of subjects: 142
Study 36156099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily with pembrolizumab 200 mg intravenously every 3 weeks and one of 7 chemotherapy regimens
Number of subjects: 70
Study 36156099 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily with pembrolizumab and chemotherapy
Number of subjects: 70
Study 36157553 — intervention group
Group type: EXPERIMENTAL
Intervention: Low/no-charge coronary artery calcium (CAC) scoring
Number of subjects: 52151
Study 36157681 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min eye covering
Number of subjects: 228
Study 36157681 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min eye covering
Number of subjects: 228
Study 36157681 — intervention group
Group type: COMPARATOR
Intervention: Programmed education only (C group)
Number of subjects: 228
Study 36157895 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (n=89)
Number of subjects: 181
Study 36157895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=92)
Number of subjects: 181
Study 36158516 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-to-globulin ratio (AGR)
Number of subjects: 85
Study 36158516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AGR
Number of subjects: 85
Study 36158516 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 85
Study 36158516 — intervention group
Group type: COMPARATOR
Intervention: Neutrophil to lymphocyte ratio (NLR)
Number of subjects: 85
Study 36158516 — intervention group
Group type: COMPARATOR
Intervention: Platelet to lymphocyte ratio (PLR)
Number of subjects: 85
Study 36158588 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy with resin yttrium-90 microspheres (SIRT) followed by gemcitabine 1,000 mg/m²
Number of subjects: 24
Study 36158638 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma circulating-tumor DNA testing using a DNA-based mutation panel
Number of subjects: 20
Study 36158638 — intervention group
Group type: COMPARATOR
Intervention: Tissue testing per standard of care including comprehensive next-generation sequencing (NGS)
Number of subjects: 20
Study 36158638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A (plasma testing)
Number of subjects: 20
Study 36158690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy (etoposide plus platinum) followed by sintilimab maintenance treatment
Number of subjects: 13
Study 36158690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab maintenance treatment
Number of subjects: 13
Study 36158692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with S-1 plus oxaliplatin (SOX)
Number of subjects: 32
Study 36158813 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-ABI
Number of subjects: 188
Study 36158813 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOW-ABI
Number of subjects: 188
Study 36158813 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified ABI measurement
Number of subjects: 188
Study 36159253 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Herts programme
Number of subjects: 717
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological measurements with ERG flash and pattern
Number of subjects: 140
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG data
Number of subjects: 140
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep settings
Number of subjects: 140
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments
Number of subjects: 140
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments
Number of subjects: 140
Study 36159928 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography for retinal structure and microvascularization
Number of subjects: 140
Study 36159943 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic resonance paced breathing (eRPB) at 0.1 Hz
Number of subjects: 77
Study 36159943 — intervention group
Group type: COMPARATOR
Intervention: Faster paced breathing sham at 0.23 Hz
Number of subjects: 77
Study 36160038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice using a mobile app for 3 weeks (10 min/day)
Number of subjects: 80
Study 36160138 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA mAIDs Registry
Number of subjects: 337
Study 36160773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing-still posture
Number of subjects: 42
Study 36161271 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCAm carriers
Number of subjects: 20624
Study 36161271 — intervention group
Group type: COMPARATOR
Intervention: BRCA wild-type (WT)
Number of subjects: 20624
Study 36161271 — intervention group
Group type: COMPARATOR
Intervention: not-tested (NT)
Number of subjects: 20624
Study 36161271 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCAm carriers in triple-negative subgroup
Number of subjects: 20624
Study 36161271 — intervention group
Group type: EXPERIMENTAL
Intervention: gBRCAm carriers in HR+/HER2 negative cancers
Number of subjects: 20624
Study 36161320 — intervention group
Group type: EXPERIMENTAL
Intervention: lovo-cel gene therapy (bb1111; LentiGlobin)
Number of subjects: 0
Study 36161511 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation therapy (ADT)
Number of subjects: 25
Study 36161783 — intervention group
Group type: EXPERIMENTAL
Intervention: ExtraTrees Classifier model
Number of subjects: 106
Study 36161783 — intervention group
Group type: EXPERIMENTAL
Intervention: lite model with 16 variables
Number of subjects: 106
Study 36161875 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased doses of inhaled corticosteroids (ICS)
Number of subjects: 1774
Study 36161875 — intervention group
Group type: COMPARATOR
Intervention: Stable doses of inhaled corticosteroids (ICS) (placebo)
Number of subjects: 1774
Study 36162011 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific immunoglobulins (CMV-Ig) administered to 10 patients in addition to standard antiviral prophylaxis.
Number of subjects: 49
Study 36162011 — intervention group
Group type: COMPARATOR
Intervention: Standard antiviral prophylaxis without CMV-Ig administered to 39 patients.
Number of subjects: 49
Study 36162011 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-Ig group
Number of subjects: 49
Study 36162059 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 483
Study 36162227 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 559
Study 36162849 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients
Number of subjects: 668
Study 36162849 — intervention group
Group type: COMPARATOR
Intervention: Potential kidney donors
Number of subjects: 668
Study 36162849 — intervention group
Group type: COMPARATOR
Intervention: Community-dwelling employed adults
Number of subjects: 668
Study 36162849 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients before transplantation
Number of subjects: 668
Study 36162849 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients at 12 months after transplantation
Number of subjects: 668
Study 36163044 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum depression (PPD) assessment using the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 164
Study 36163044 — intervention group
Group type: COMPARATOR
Intervention: Comparison of observed PPD rate during lockdown to pre-pandemic rate
Number of subjects: 164
Study 36163044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EPDS> 12 or PPQ > 6 scores
Number of subjects: 164
Study 36163044 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with EPDS> 12
Number of subjects: 164
Study 36163163 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m2 in cohort 1 (triple-negative)
Number of subjects: 40
Study 36163163 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and/or paclitaxel in cohort 2 (hormone receptor-positive)
Number of subjects: 40
Study 36163415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with modification (n=39)
Number of subjects: 206